Status note USDA approval December 2025; phased launch initiated second quarter 2026.
AdTab
Approved · ActiveModality: chewable tablet
Indications
Flea and tick treatment for dogs and cats(Approved)
Status note Approved and launched in the U.K. (April 2025).
lotilaner royalty interest
Approved · ActiveModality: ophthalmic solution
Aliases lotilaner ophthalmic solution 0.25% (marketed by Tarsus as XDEMVY)
Partnerships Tarsus Pharmaceuticals (license agreement); Blackstone (May 2025 purchase and sale agreement for rights to proceeds from qualifying future U.S. royalties and certain global sales milestones for $295M; Elanco retains ex-U.S. royalties and U.S. royalties after August 24, 2033)
Indications
Demodex blepharitis (human)(Approved)
Status note Royalty/milestone interest in human health application of lotilaner marketed by Tarsus as XDEMVY; Elanco retains rights to royalties/milestones from future expansion of lotilaner in other human health applications.
Per-asset detail extracted from the 10-Q filed 2026-08-05. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Institutional holders
Fund
Shares
Q/Q change
% of portfolio
Filing
ADAR1 Capital Management
0
-20,000
0.00%
2026-08-14
Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.